Nature Medicine, Published online: 25 June 2025; doi:10.1038/s41591-025-03776-7
In a reverse-translational study followed by a clinical trial, the targeting of antigen-presenting mast cells was identified as a therapeutic approach to overcome anti-PD-1 resistance in patients with metastatic triple-negative breast cancer who experienced clinical benefit when treated with the mast cell stabilizer cromolyn.
